Concentrations	9 Months Ended
Jun. 30, 2024
Concentrations [Abstract]
Concentrations	NOTE 9 – Concentrations *Revenue* Through March 31, 2024, one customer accounted for all of the Company’s product and collaborations revenue. During the three months ended June 30, 2024, the Company initiated a limited commercial launch of our OneRF ablation system and sold to two additional customers, who accounted for approximately 20% of the Company’s product revenue for the period. The OneRF Products are not covered by a distribution agreement. *Supplier concentration* One contract manufacturer produces all of the Company’s Strip/Grid Products and sEEG Products and another supplier was responsible for the development of the Company’s OneRF Ablation system.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/275/tableOfContent

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration